Fathi, A. T., Issa, G. C., Wang, E. S., Erba, H., Altman, J. K., Balasubramanian, S. K., … Zeidan, A. M. (2024). Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. In Blood (Vol. 144, pp. 2880–2880). American Society of Hematology. https://doi.org/10.1182/blood-2024-199170

Fathi, Amir T., Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, et al. “Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007.” In Blood, 144:2880–2880. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-199170.

Fathi AT, Issa GC, Wang ES, Erba H, Altman JK, Balasubramanian SK, et al. Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. In: Blood. American Society of Hematology; 2024. p. 2880–2880.

Fathi, Amir T., et al. “Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 2880–2880. Crossref, doi:10.1182/blood-2024-199170.

Fathi AT, Issa GC, Wang ES, Erba H, Altman JK, Balasubramanian SK, Roboz GJ, Schiller GJ, McMahon CM, Palmisiano ND, Juckett MB, Madanat YF, Rotta M, Pratz KW, Yaghmour G, Nadiminti K, Wei H, Riches M, Corum D, Leoni M, Dale S, Zeidan AM. Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood. American Society of Hematology; 2024. p. 2880–2880.